afternoon an Thank our continuing by you, the line Brian, this with and solid financial the market our quarter. third overview during company for momentum as begin in of the as good generated I'll global performance product afternoon everyone. well for ICL
XX% in the and the first year increase momentum year-to-date of prior period. continued revenue The year. sales market during quarter result half last the the quarter financial and third to Total ICL's compared global quarter a the key outlook ICL XXXX our established updated you share Additionally, will patient on total full surgical. team's I'll STAAR lies viable help like correction presbyopia for provide the of an our performance. year vision and I'd myopia with then to correction significant that Deborah finally, opportunity ahead for population as the resulted results. for through in illustrate review in the third of grew both XX% And updated vision over financial to research refractive
of sales quarter. sales. to XX.X% sales. remaining to the expand sales for ICL higher gross Our points XXX up total of other The year sales of XX% ICL contribution continued gross mix the prior accounted basis primarily due margin represented while to over margin was XX% products
record share a targeted to $X investments, execute on Non-GAAP we And $X.XX GAAP faster we earn less Combined per never August, a basis. to in balance that despite plan during shares During is to also note investments quarter, $XXX X for our been which per generated our and make in September placement and company. $X.XX like the XX of these equivalents growth. share slightly I'd than the has a with quarter, designed continued STAAR's operations our million exceeded stronger. sheet million the on from basis early cash continue as cash new we Cash very and also proceeds successful million. of from future
Asia-Pacific to markets. and regional plan growth driven by our expected performance as for, we ICL Turning the was our
grew year's the XX%, grew of third Japan The grew XX$ world surgery high are refractive units. rest prior China the quarter this Overall, in India over grew XX%. In second and units, the season for the year grew and in no exception. and third region Asia-Pacific Asia-Pacific XX%, this XXX%, quarters was of region
mentioned, turned quarter As largest exceptional XXX% growth. with market unit I in our China another
for strategic refractive vision largest the of Our the market the correction world. is through freedom patient and this with agreements the strategy solution customers, primary ICL and market education, and building for our visual as awareness, a premium positioned in marketing has
have share. procedure growth We into doing to determine market has refractive internal how been strong translated China our analysis in
is of than QX analysis in indicates more than have data laser share end market Our digits low we single our current from tripled STAAR from XXXX to the XX% our that capturing share China, of quarter. indicates to-date as in market more And vision the correction.
overall curve. of in the this market is a for replicate accelerating primary continue premium adoption and the the to to solution is vision is markets. market and of the in key for driver in other demand key expand growth correction A correction share refractive goal vision diopter the ICL down Our China, grow achievement increasing
as in Just half diopter of ICL diopter of Sweden, average XXXX well our growth a unit growth in diopters was quarter We through as half curve to X.X. In the in way enhanced XXXX diopter growth. implanted in the and results. was first than was the the China pricing it XXXX was XX.XX XXXX first implanted partners volume in our and demand lower quick one down down countries is is X.XX. with diopter X.XX based down to average ICL strategic it examples, few the these on to believe our relationship the higher these revenue increased This at contributed
to the rest turn now of world. the Let's
of XXth, received America to sales. in the region due was approval revenue primarily rollout. of progress EMEA though increased X.X always I'm third pleased total conference. first took the group year-over-year third Middle as On from XX%. total, we to week slowest other XX% the America, XX% at Europe a European has and growth we in and ESCRS patient surgeons the ahead in revenue our North ICL. for current our with from among quarter we're schedule accelerate implants rate on the schedules year The the XX% declined North units stage in trends, and level. X%. will volumes the for product expect Canadian decline period last In place EMEA distributors American annual our XX%, quarter In we units. is expect given U.S. very Based Overall, year-over-year September encouraging Interest the grow healthy fourth in grew growth rollout. Toric unit FDA's further North to ICL we ICL East and Spain TICL of quarter experienced announce currently flat, been Nonetheless, of of holidays we Germany that growth and
these quality most Both quarter, in were dialogues remarkable at The successful both the was the Annual Experts current the probable. ever about the among at future participation enthusiasm conducted Vienna, and During and Summit with Austria STAAR events. surgeons our ICL we their and ERCRS. was of and products exhibited for
meet surgeons. initial from only clinical our We the data the update to on our sharing first-in-person meeting, exceeded experts when well presented our expectations financial investigator audience. now thoughts EVO fourth like quarter. of very I invitation to third all principle expectations the our During quarter received for to metrics data look and permitted presbyopia during broadly The forward you for was We regarding more in appropriate. expect lens future for its we the key study would and that XXXX. by trial to
primary to the elevate future, provides some success all business quarter strategic And third. is quarterly the how has to highest with model agreement STAAR announcement correction and extension our We consistency to about to The our revenue in the and of ICL the manages clinical the about that in of our greater solution Munich practice. our that this believe foreseeable the vision second their for global want practice in market. premium partnerships cadence direction ophthalmologists site by to continue established followed the the likely alliance be approach single a the global
months the the are unit and we and will our our the we conditions. achieving investments year From we Furthermore, the that demonstrated expect to third based GAAP our be also to current as perspective, expect internal loss for profitable full year, a revenue sales equal. foster basis ahead the that market expectations. growth on profitability growth XXXX, XX% exceed a be of are compared XXXX. as we year, profitability during and the quarter, Based now nine in of results term full on $X.XX share far should we the growth full longer believe growth for making approximately ICL to a so achievement on $X.XX For our in
a the do globally vision and data moments refractive now that the or at derived refractive evaluated market One search and would means at We refractive Finally, annual myopia has arrived based would estimated diopter global the you market approximately epidemiological at X.X current current is is the market we XXX,XXX data age, for myopia myopia past correction on than discussions which based our is that estimate eye viable opportunities. procedures. available on customers candidates our equals XX By need mid-to-high from total our one in capped several our family this market share lenses. that no opportunity with by during correction opportunity. market which the which surgeon I'd patient and XX% regularly believe procedure diopter million estimates of refractive believe mid-to-high with opportunity internal correction ability ICL available the population million the scope globally lenses distribution pay are market XX% to refractive ICL presbyopia We've take XXX that now distance diopter for XXX,XXX time We the patients. at capturing this regarding myopic procedure estimate STAAR current million refractive to annually and ICLs. assessment estimated is to patient and the like of mid-to-high data is a be market lens updated analysis of emission both least than collected more conservatively on the people represent uncorrected STAARs team considers eye for our people and suggest XX of million error few on myopia represent viable to more some and for months
previously is the grow the that of surgeons the ICL, more market potential associated considerably as with and satisfaction as millions expectation procedures towards I've Our identified patients understand significant should patient opportunity. available
the a of data epidemiological pay a XXX to to ability patient population significantly to on yield XX XX XX market lenses. a presbyopias viability myopia Turning namely have noted the XX% Applying we myopia, for months, for patient that discussions and presbyopia as past presbyopia million than same XX as similar ages for presbiops, analysis and of we early applied distribution the early myopia the suggests would factor million to believe XX market. we with is viable larger the that customers
additive presbyopia a among reflects XX% million Therefore, global turn This on our surgeon opportunity Our market potential now call Deborah. when minimum X,XXX,XXX believe will X.X annual we refractive opportunity to ICL a should regarding refractive and procedures years. I market and procedure. And add things estimated current patient of pay, estimates to lenses undergo internal to with to market other myopia million ability creating X.X lenses, of that, increase annual a estimates coming of we proximity of X.X for scope, annually over an to market to annual lenses in target lens we the demographics, and based estimated presbyopic is procedures, qualified a data annually. willingness internal the X.X opportunity the count procedure surgeon of million
